Abstract: A method of treating trypanosomiasis in a mammal, which entails administering to a mammal in need thereof an effective amount of medicinal producting comprising a plant extract comprising one or more compounds of formula (I).

Abstract: The invention relates to the use of quinolines having general formula (I), wherein R1 denotes H; alkyl C1-C15; alkenyl or alkynyl C2-C15; —CHO; heteroaryl; alkyl C1-C15 or alkenyl or alkynyl C2-C7 comprising at least one substituent selected from among O, halogen, —OH, —CHO, —COOH, aryloxycarbonyl, alkyloxycarbonyl C2-C8, alkenyloxycarbonyl C3-C9, nitrile, aryl, heteroaryl, arylsulphone, alkylsulphone C1-C7, thioalkyl or aminoalkyl C1-C7; alkenyl C2-C 7 bearing at least one substituent selected from among NH2, aleoxy C1-C7, phenoxy, cycloakyl C3-C6 or heteroaryloxy, alkenyl or alkynyl C2-C15 comprising at least one trialkylsilyl C1-C7; R2, in position 3, 6 or 8, denotes H; halogen; —OH; —CHO; —COOH; alkyl or aleoxy C1-C7; —NH2; alkenyl C2-C7; or alkynyl C2-C10; R1 and R2 do not both denote H.

Abstract: The invention concerns the use of canthin-6-one from plant extracts containing same, in particular canthin-6-one in the form of a Zanthoxylum chiloperone of the angustifolium variety, and some of its derivatives for making a medicine for the treatment of trypanosomiases, in particularly for treating Chagas disease.

Abstract: The invention relates to the use of quinolines having general formula (1), wherein R1 denotes H; alkyl C1-C15; alkenyl or alkynyl C2-C15; —CHO; heteroaryl; alkyl C1-C15 or alkenyl or alkynyl C2-C7 comprising at least one substituent selected from among O, halogen, —OH, —CHO, —COOH, aryloxycarbonyl, alkyloxycarbonyl C2-C8, alkenyloxycarbonyl C3-C9, nitrile, aryl, heteroaryl, arylsulphone, alkylsulphone C1-C7, thioalkyl or aminoalkyl C1-C7; alkenyl C2-C7 bearing at least one substituent selected from among NH2, aleoxy C1-C7, phenoxy, cycloakyl C3-C6 or heteroaryloxy, alkenyl or alkynyl C2-C15 comprising at least one trialkylsilyl C1-C7; R2, in position 3, 6 or 8, denotes H; halogen; —OH; —CHO; —COOH; alkyl or aleoxy C1-C7; —NH2; alkenyl C2-C7; or alkynyl C2-C10; R1 and R2 do not both denote H. The invention is used for the preparation of a medicine to treat protozoan and retrovirus co-infections.

Abstract: Substituted quinolines having formula (1), wherein R.sub.1, R.sub.3, R.sub.4, R.sub.5, R.sub.6, and R.sub.7 each independently represent a hydrogen atom, a linear or branched C.sub.1-7 alkyl, alkenyl, epoxy-alkyl or mono/polyalcohol group; an amine group or an amide group, an OR group in which R is hydrogen or a C.sub.1-7 alkyl or alkenyl group or a phenyl group; and R.sub.2 is an OR group in which R is as defined above, or a C.sub.1-7 alkyl alkenyl or epoxyalkyl group, a phenyl, phenol, methylenedioxyphenyl, or dimethoxyphenyl group, or a C.sub.1-7 alkyl, alkenyl or epoxyalkyl group, a phenyl, phenol, methylenedioxyphenyl, or dimethoxphenyl group or a C.sub.1-7 alkyl, alkenyl or epoxy-alklyl group comprising at least one of the following substituents: a C.sub.1-4 alkyl or alkenyl group; a phenyl, phenol, dimethylphenyl, dimethoxyphenyl or methylenedioxphenyl group; or an OR group in which R is hydrogen or a C.sub.1-4 alkyl or alkenyl group; or an NHR group in which R is hydrogen or a C.sub.